Abstract
Chronic Lymphocytic Leukemia Abstract. CLL is an indolent B-cell lymphoma characterized by a leukemic course. It is clinically and biologically very heterogeneous. The disease is preceded by a condition called monoclonal B lymphocytosis (MBL). The treatment of CLL has changed dramatically in recent years. Chemoimmunotherapy is being replaced by new molecularly targeted therapeutic modalities like B cell receptor inhibitors and BCL-2 regulators of programmed cell death. When to initiate therapy and what "new" drug combinations to use in which line of treatment are issues currently addressed in clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
